Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMBS | P08397 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MMP12 | P39900 | 7/20 | 0.35 |
| ▸ | MMP2 | P08253 | 6/20 | 0.35 |
| ▸ | MMP9 | P14780 | 6/20 | 0.35 |
| ▸ | MMP1 | P03956 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551459 | 0.84 | GAA (0.58) | HMBSKDM4EGLAGAAMMP2 | |
| SCHEMBL402047 | 0.81 | LMNA (0.51) | KDM4EGLAGAAMMP2LMNA | |
| SCHEMBL28670649 | 0.74 | — | — | |
| SCHEMBL7193830 | 0.74 | GABRA1 (0.39) | KDM4EGLAGAAMMP12MMP2 | |
| SCHEMBL1126943 | 0.71 | HMBS (0.42) | HMBSKDM4EHPGDHSD17B10USP2 | |
| SCHEMBL18900582 | 0.71 | HMBS (0.42) | HMBSKDM4EGAAMMP12MMP2 | |
| SCHEMBL17624955 | 0.71 | ALOX15 (0.42) | HMBSGAAHPGDSMN1; SMN2NPC1 | |
| SCHEMBL509243 | 0.70 | ALDH1A1 (0.40) | HMBSKDM4EGAALMNAHPGD | |
| SCHEMBL3623797 | 0.70 | HMBS (0.40) | HMBSKDM4EHPGDHSD17B10USP2 | |
| SCHEMBL70624 | 0.69 | GAA (0.67) | KDM4EGLAGAAMMP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024226422-A1 | HELICASE DEGRADERS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2019178119-A1 | AMINOCOUMARIN COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | AAAS, PROC, AADAC | HMBS 48/4885KDM4E 3551/4885GLA 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.